Nyxoah S.A. (NASDAQ:NYXH) Short Interest Update

Nyxoah S.A. (NASDAQ:NYXH) was the recipient of a large increase in short interest in February. As of February 28th, there was short interest totalling 100,200 shares, an increase of 27.2% from the February 13th total of 78,800 shares. Approximately 0.7% of the shares of the company are sold short. Based on an average daily trading volume, of 43,000 shares, the short-interest ratio is currently 2.3 days.

Institutional Trading of Nyxoah

A number of large investors have recently added to or reduced their stakes in NYXH. Kovack Advisors Inc. bought a new stake in Nyxoah in the 3rd quarter worth approximately $96,000. LPL Financial LLC bought a new position in shares of Nyxoah during the 4th quarter valued at approximately $102,000. Walleye Capital LLC increased its position in shares of Nyxoah by 23.9% during the 4th quarter. Walleye Capital LLC now owns 14,831 shares of the company’s stock valued at $119,000 after purchasing an additional 2,862 shares during the last quarter. Ameriprise Financial Inc. bought a new position in shares of Nyxoah during the 4th quarter valued at approximately $135,000. Finally, Geode Capital Management LLC increased its position in shares of Nyxoah by 19.4% during the 4th quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock valued at $137,000 after purchasing an additional 2,774 shares during the last quarter.

Nyxoah Price Performance

NYXH traded up $0.19 on Tuesday, hitting $10.60. 70,939 shares of the company’s stock traded hands, compared to its average volume of 45,072. The company’s 50 day simple moving average is $10.30 and its 200-day simple moving average is $9.21. The firm has a market cap of $361.04 million, a price-to-earnings ratio of -5.67 and a beta of 1.42. Nyxoah has a one year low of $6.76 and a one year high of $20.00. The company has a current ratio of 5.28, a quick ratio of 4.95 and a debt-to-equity ratio of 0.21.

Nyxoah (NASDAQ:NYXH) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03). Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. The firm had revenue of $1.35 million during the quarter, compared to the consensus estimate of $2.02 million. As a group, research analysts anticipate that Nyxoah will post -1.91 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on NYXH shares. Stifel Nicolaus lowered their price objective on Nyxoah from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Nyxoah in a research report on Friday, December 13th.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.